B+
Bull case
25%
Probability
Target price
$9.00
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
ZURA
Zura BioDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Runway now appears materially improved through at least end-2028, and two ongoing Phase 2 tibulizumab studies give Zura multiple shots on goal over the next 15 months [#10-K-2026-03-19].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -3.8.
What can break
Clinical readouts for both lead studies can slip or disappoint, with outsized downside in a single-lead-story biotech.
Momentum
67
Value
41
Sentiment
54
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $5.00 · Bull $9.00 · Bear $2.50Analysis 2026-04-15; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $18.83
Why
Momentum67 · Δ7d +11.5
Value41 · Δ7d 0.0
Sentiment54 · Δ7d -3.8
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -3.8.
Contradictions & invalidation
- • Clinical readouts for both lead studies can slip or disappoint, with outsized downside in a single-lead-story biotech.
- • Despite improved runway, future equity issuance remains possible if timelines expand, costs rise, or additional programs are advanced.
- • This remains a low-coverage, pre-revenue biotech with no approved products, no completed Phase 2/3 trials, and a thesis still dominated by future readouts rather than operating proof [#10-K-2026-03-19].
Catalyst clock
2026-04-15
February financing materially extends runway
Lead driver: Sentiment · See AI snapshot
Momentum
67
9% active weight
Current posture
7d trendImproving
Δ7d
+11.5
Δ21d
-18.8
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
54
62% active weight
Current posture
7d trendSoftening
Δ7d
-3.8
Δ21d
-4.7
Why this grade
Composite grade D. Momentum 66.7 / Value 41.2 / Sentiment 53.6
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-04-15. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$5.00
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$2.50
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$544.31M
Beta
0.21
Shares Out
95.83M
P/E (TTM) · Derived
-5.4
P/S (TTM)
-
P/FCF (TTM) · Derived
-7.10
Rev YoY
-
EPS YoY
+22.3%
Gross Margin
-
Op Margin
-
Net Debt
-$109.41M
Current Ratio
12.90
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data